Anti-platelet drugs, pharmacogenomics and stent thrombosis: What’s new?
Stent thrombosis is a catastrophic complication of percutaneous coronary intervention (PCI) and is associated with a mortality of 25 to 40%. The perception that stent thrombosis is very low in all patients has resulted in a lack of adherence to professional guidelines. New data to identify patients...
Guardado en:
Autor principal: | John Benjamin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
South African Heart Association
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/30784cb229da45439b3270debb1493bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention in Patients Treated With Potent P2Y12 inhibitors ‐ a VALIDATE‐SWEDEHEART Substudy
por: Sofia Bergman, et al.
Publicado: (2021) -
Long term safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent-a real-world data from India
por: Basant Kumar, et al.
Publicado: (2021) -
Emerging Microfluidic Approaches for Platelet Mechanobiology and Interplay With Circulatory Systems
por: Yingqi Zhang, et al.
Publicado: (2021) -
Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials
por: Yong Zhu, et al.
Publicado: (2021) -
A Case of Stent Fracture and Very Late Stent Thrombosis 15 Months after Drug-Eluting Stent Implantation
por: A Ghaemian,, et al.
Publicado: (2009)